Charles River Laboratories’ Post

We are thrilled to announce the publication of a 10-day study conducted by Charles River, comparing Kytopen’s Flowfect Tx™ cellular engineering platform with two commercially available electroporation platforms. A key finding in this study was the considerably higher yields of gene-edited, viable cells with the Flowfect Tx™ platform. “We have a GMP-scale manufacturing platform that has already been evaluated for tech transfer and this study further highlights the ease of implementation to develop superior yields of final drug substance", said Kevin Gutshall, Chief Commercial Officer at Kytopen. To access the full press release: https://lnkd.in/gJnfCgMX To access the summary of the study, Making Gains in Non-Viral Engineering of T Cells for Cell Manufacturing, visit https://bit.ly/3ANGxxF  #celltherapy #regenerativemedicine #tcells #cancer #cancerresearch #geneediting #innovation

Let's catch up and talk drug discovery. If you have specific questions we can set up a time to meet.

The peer-reviewed journal Neoplasia has published a paper, co-written by our scientists along with Professor Greg Thurber’s laboratory at the University of Michigan (University of Michigan Chemical Engineering).   The paper outlines encouraging data from PSMA-positive preclinical models of Crescendo’s half-life extended CD137 x PSMA bispecific, demonstrating superior tumour penetration, enhanced target access and T cell activation.   Read today’s press release here: https://lnkd.in/dsDTgZq   Follow this link to read the full paper: https://lnkd.in/ec9rnYRZ #Cancer #Biotech #Therapeutics

HydraSpace™, a compact and highly polar spacer technology. HydraSpace™ enables efficient attachment of the most challenging hydrophobic payloads to an antibody, and with its branching capability two distinct payload types can be attached to the same antibody – a dual-warheaded ADC format– a key strategy in the eradication of cancer stem cells and the treatment of multi drug resistant forms of cancer. Forming an integral part of every toxSYN™ linker-payload, HydraSpace™ bears a negative charge at physiological pH and improves therapeutic efficacy, tolerability, pharmacokinetics, and manufacturability. Visit our website linked below to learn more about HydraSpace™. #drugdevelopment #ADCs #biotech

In a recent study published in Cell Reports, a novel engineering strategy was used to generate EGFR-specific CARs. Results show that the generated binding domainsenable CAR T cells to distinguish between active and inactive EGFR for improved solid tumor specificity. Learn more about our CAR-T capabilities for your next preclinical immuno-oncology study: https://hubs.la/Q02tQNKG0. [1] Dobersberger M et al. An Engineering Strategy to Target Activated EGFR with CAR T Cells. Cell Reports. April 22, 2024;4(4): 100728. #TargetedTherapies #FightCancer #IO #HumanizedMice #CancerResearch #EGFR

The Smith Research Lab introduces a new era in drug delivery evaluation with theranostic tools. Dive into our research combining synthesis and bioanalytical methods to create drug-fluorophore conjugates. Witness the activation of theranostic tools inside cancer cells, bringing us one step closer to personalized medicine. 🌐 https://lnkd.in/eB-3H5UD #SmithResearchLab #DrugDeliveryEvaluation #TheranosticTools #SynthesisMethods #BioanalyticalApproaches #DrugFluorophoreConjugates #CancerCellActivation #PersonalizedMedicine #BiomedicalResearch #ScientificInnovation #MedicalAdvancements #ResearchBreakthroughs #BowieStateUniversity #NaturalSciences #STEMResearch #TherapeuticAdvancements #Biochemistry #ScienceInnovation #MedicineDevelopment

Pioneering Medical Research with Terbium-161 🔬 Terbium-161 exhibits exciting potential as a radiopharmaceutical element. With its ability to emit beta radiation, it can precisely target cancer cells, providing prospects for more effective therapeutic solutions. Bellow is a scan we acquired using our benchtop modality, the γ-eye, on a healthy subject. We are excited to provide scientists with the tools they need. Embracing them translate ideas, into outcomes. #molecularimaging #research #terbium161 #theranostics

🚨 New Customer Case Study Alert! 🚨 🔬Discover the latest work from Università Ca' Foscari Venezia, which demonstrates drug-loaded liposome production using Fluigent’s pressure controllers and flow sensors. 📄A recent Scientific publication by Saorin et al. (2024) revealed how our system effectively encapsulate amiodarone in liposomes, achieving precise control over size, monodispersity, and encapsulation rate. The results indicate that amiodarone shows promising candidate as a drug for ovarian cancer studies. Check out the full study and learn more about our new liposome production package here: https://bit.ly/4bCZ79e | https://bit.ly/4bAFuOW #liposome #encapsulation #drugdelivery #ovariancancer #lipidnanoparticles #microfluidics

Let’s de-risk your drug development journey 🚀 At Physiomics plc, our expert team uses advanced data science and mathematical modelling techniques to predict and enhance therapeutic outcomes with precision. We’re here to help you navigate the complexities of R&D across pre-clinical, translational, and clinical stages. Learn how our proven solutions can guide your decisions from discovery to the clinic: https://lnkd.in/e7rA8RCH #Cancer #DrugDevelopment #CancerDrugs #CancerSimulation #InSilico #QSP #MathematicalModelling #PKPD #MechanisticModelling #Oncology #ClinicalTrials #ResearchandDevelopment #CancerResearch #BioTech #StatisticalModelling #MachineLearning #Pharma #TranslationalModelling #PYC